Ann: Appendix 4D and Half Year Accounts, page-2

Congratulations to CEO Nigel Lange and the OncoSil Team on a Stellar Half-Yearly Performance!

Dear OncoSil Community,I hope this message finds you well. Today, I am thrilled to extend my congratulations to our CEO, Nigel Lange, and the entire OncoSil team on the remarkable achievements outlined in our latest Half Yearly Report – Appendix 4D, covering the six months ended 31 December 2023.

The report showcases significant milestones in both the clinical trial program and the commercialisation strategy of the OncoSilTM device, underscoring the dedication and expertise of our team. The successful completion of the second round of stakeholder meetings for the G-BA trial in Germany, the advancement of the TRIPP-FFX Clinical Study, and the initiation of the PANCOSIL Investigator-Initiated Clinical Trial are testament to our commitment to innovation and excellence in healthcare.

The commercialisation efforts have not only gained momentum but have also expanded our global footprint. With the OncoSilTM device now being actively used in Spain, Italy, Greece, and Israel, and the recent exclusive distribution agreement for Turkey, we are making significant strides in making this groundbreaking treatment accessible to more patients worldwide.

The financial highlights of the report, including a revenue from commercial sales of approximately $87,956 and a cash balance of $4.9m as of 31 December 2023, reflect our financial position. Additionally, the receipt of a research and development tax refund of around A$1.1m from the Australian Government further bolsters our resources for ongoing and future projects.

The strategic enhancement of our Board's technical skillset, with the appointments of Douglas Cubbin and Dr Ga briel Liberatore, positions us even more strongly for the challenges and opportunities ahead.I would like to express my appreciation to Nigel and every member of the OncoSil team for their unwavering dedication and hard work.

It is your expertise, commitment, and passion that drive our success and make a real difference in the lives of those we serve.

Let us all look forward to continuing this journey of innovation and success together, making the OncoSilTM device a beacon of hope for patients around the globe.

Warmest regards, Ozzie